Biomet Deutschland GmbH

Products for the treatment of bone and connective tissue diseases

Biomet Merck was established in 1998 as a joint venture of Biomet Inc. (USA) and Merck KGaA, Darmstadt and created one of the market leading orthopaedic companies in Europe. In March 2004, the Biomet Merck Group was renamed upon the acquisition of Merck’s 50% interest in the parties’ European joint venture and became “Biomet Europe”. The Biomet Europe Group is headquartered in Dordrecht (The Netherlands) and represented by subsidiaries in 18 European countries, one of them also in Germany, of which the address is given below.

Roger P Van Broeck, President, CEO
Paul SA Renaud, Vice President, CFO
Antje-Christiane Petersen, Dr., Vice President, General Counsel Biomet Europe BV

Gustav-Krone-Straße 2
14167 Berlin
Germany
Phone: +49-30-845-81-0
Fax: +49-30-845-81-110

The company produces various products that can be grouped as follows: (1) Biomaterials include blood derivates, bone substitutes, haemostatics, antibiotic carriers, and woundhealing; (2) joint replacements include the knee, shoulder, foot, hand, elbow, and the hip; (3) spine-related products such as spinal implants, spinal fixation systems, and vertebroplasty; (4) trauma-related products such as intra-medullary nails, fixators and growth stimulators.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.